That being said, there are also a handful of clinical studies and trials that analysed the mechanistic relevance of NO/NOS dysregulation in cancer therapy-associated CTX, and assessed its potential in the uncovering of predictive biomarkers and development of therapeutic options for chemotherapy related cardiac dysfunction. The gene discussed is NOS1; the disease is cancer.